Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CRYO CELL INTERNATIONAL INC
Report date September 22, 2020 · Filed September 24, 2020
Section 16 reporting ended · disclosed 2020-09-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,078 |
Reported balance
Holding disclosure · report date 2020-09-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 30,078 |
| Common StockSEC Table I · non-derivative | IndirectJoint with Spouse | 71,693 |
Reported balance
Holding disclosure · report date 2020-09-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 71,693 |
| Common StockSEC Table I · non-derivative | IndirectBy IRA | 15,100 |
Reported balance
Holding disclosure · report date 2020-09-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 15,100 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.53 · Expires 2029-08-30 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2020-09-22 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 20,000 F1: On August 30, 2019, the reporting person was granted 20,000 stock options, vesting in three equal installments beginning on the date of grant. Effective September 15, 2020, the Compensation Committee accelerated the vesting of 6,667 stock options in connection with the reporting person not being nominated to the Company's board of directors |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.74 · Expires 2029-11-25 | Direct | 5,300 |
Reported balance
Holding disclosure · report date 2020-09-22 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 5,300 F2: On November 25, 2019, the reporting person was granted 5,300 stock options, vesting in twelve equal installments beginning on the date of grant. Effective September 15, 2020, the Compensation Committee accelerated the vesting of 883 stock options in connection with the reporting person not being nominated to the Company's board of directors |
Filing footnotes · ownership attribution and instrument terms
F1: On August 30, 2019, the reporting person was granted 20,000 stock options, vesting in three equal installments beginning on the date of grant. Effective September 15, 2020, the Compensation Committee accelerated the vesting of 6,667 stock options in connection with the reporting person not being nominated to the Company's board of directors
F2: On November 25, 2019, the reporting person was granted 5,300 stock options, vesting in twelve equal installments beginning on the date of grant. Effective September 15, 2020, the Compensation Committee accelerated the vesting of 883 stock options in connection with the reporting person not being nominated to the Company's board of directors
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2019 Filed Dec 13, 2019 15:11 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 5,300 | $7.74 Strike: $7.74 | $41,022.00 |
DisclosureSEC source: 0000899243-19-029115 · doc4.xml · derivative · entry 5 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2026-11-25 F2 · derivative.exercise_date: Stock options vest at a rate of 1/12 per month commencing on November 25, 2019. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:16 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 20,000 | $7.53 Strike: $7.53 | $150,600.00 |
DisclosureSEC source: 0000899243-19-022750 · doc4.xml · derivative · entry 4 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-08-30 F1 · derivative.exercise_date: Stock options will vest 1/3 upon date of grant, 1/3 on August 30, 2020 and 1/3 on August 30, 2021. Read SEC document |
| April 17, 2019 Filed Apr 24, 2019 20:30 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | PurchaseCommon Stock | 3,853 | $6.90 | $26,585.70 |
DisclosureSEC source: 0000899243-19-011038 · doc4.xml · nonDerivative · entry 1 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,078 Read SEC document |
| October 23, 2018 Filed Oct 23, 2018 21:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | PurchaseCommon Stock | 5,000 | $6.80 | $34,000.00 |
DisclosureSEC source: 0000899243-18-027298 · doc4.xml · nonDerivative · entry 1 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,225 Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 21:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | PurchaseCommon Stock | 1,975 | $7.90 | $15,602.50 |
DisclosureSEC source: 0000899243-18-023731 · doc4.xml · nonDerivative · entry 2 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,225 Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 21:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | PurchaseCommon Stock | 1,000 | $8.00 | $8,000.00 |
DisclosureSEC source: 0000899243-18-023731 · doc4.xml · nonDerivative · entry 1 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,250 Read SEC document |
| August 24, 2018 Filed Aug 27, 2018 20:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | PurchaseCommon Stock | 40 | $8.00 | $320.00 |
DisclosureSEC source: 0000899243-18-023300 · doc4.xml · nonDerivative · entry 1 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 20:30 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | PurchaseCommon Stock | 550 | $8.00 | $4,400.00 |
DisclosureSEC source: 0000899243-18-023025 · doc4.xml · nonDerivative · entry 2 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,210 Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 20:30 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | PurchaseCommon Stock | 1,500 | $8.05 | $12,075.00 |
DisclosureSEC source: 0000899243-18-023025 · doc4.xml · nonDerivative · entry 1 Ellis Arthur · CIK 0001750387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,660 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.